Phase II trial of elotuzumab with pomalidomide and dexamethasone for daratumumab-refractory multiple myeloma.
Blood Cancer J
; 14(1): 152, 2024 Sep 05.
Article
in En
| MEDLINE
| ID: mdl-39237502
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Thalidomide
/
Dexamethasone
/
Antineoplastic Combined Chemotherapy Protocols
/
Antibodies, Monoclonal, Humanized
/
Multiple Myeloma
Limits:
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
Blood Cancer J
Year:
2024
Document type:
Article
Affiliation country:
Country of publication: